PSNL News and Press, Personalis Inc. From 06/21/21

Personalis, Inc. is a global cancer genomics company offering genomic sequencing and data analytics solutions for comprehensive molecular data analysis for patient-specific cancers and immune responses. Personalis' products include: 1) ImmunoID NeXT, a universal cancer immunogenomics ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, announced today that it has delivered the 125,000th whole human genome sequence dataset to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). First contracted ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the Oppenheimer MedTech, Tools & Diagnostics Summit on Wednesday, May 26, 2021. Interested parties may access the pre-recorded and archived web...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at Biomarkers Week Online 2021. The presentation , titled “ImmunoID NeXT Platform® for comprehensive tumor immunogenomics and advanced biomarker d...

Analysts weigh in on potential of COVID-19 patent waiversYesterday's announcement that the U.S. would support a waiver of IP protections for COVID-19 vaccines led to a slide in vaccine makers.However, several analysts believe the potential impact may be overhyped as other countries also oppos...

Stealth BioTherapeutics (MITO) +58% after showcases data for Elamipretide.Luokung Technology Corp. (LKCO) +22% on announcing favorable ruling granting preliminary injunction.Nemaura Medical (NMRD) +23% on 200K sugarBEAT sensors order.American Shared Hospital Services (AMS) +28%...

Personalis, Inc. (PSNL) Q1 2021 Earnings Conference Call May 05, 2021 05:00 PM ET Company Participants Caroline Corner - IR John West - President and CEO Aaron Tachibana - CFO Conference Call Participants Doug Schenkel - Cowen Vidyun Bais - BTIG Mike Matson - Needham & Company Swayampakul...

Personalis (PSNL): Q1 GAAP EPS of -$0.29 beats by $0.07.Revenue of $20.88M (+9.0% Y/Y) beats by $0.45M.Press Release For further details see: Personalis EPS beats by $0.07, beats on revenue

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the first quarter ended March 31, 2021. First Quarter Highlights Record quarterly revenue of $20.9 million in the first quarter of 2021...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 2021 Bank of America Healthcare Conference on Thursday, May 13, 2021 at 5:00 p.m. Eastern Time. About Personalis, Inc. Personalis, Inc. is ...